RxDoctor Payments Data

Shelby Willingham, PA

Physician Assistant · Bandera, TXNPI 1912606674

Payments from drug & device makers

$5,255in general payments, 2019–2025

Across 168 payments — averaging $31.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$850
  • Amgen$742
  • AstraZeneca$387
  • Axsome Therapeutics, Inc.$315
  • Johnson & Johnson$304
  • Lilly USA, LLC$292
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,255 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$31,341
Medicare patients
226
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol44$36,174
JardianceEmpagliflozin20$24,497
OzempicSemaglutide14$18,297
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,355
MounjaroTirzepatide14$14,844
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,281
Albuterol Sulfate HfaAlbuterol Sulfate74$1,854
Gabapentin60$904
Omeprazole49$659
Rosuvastatin Calcium116$645
Betamethasone Dipropionate18$618
Methylprednisolone82$587
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$585
Hydroxyzine Hcl42$555
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip19$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$387$43,45556 claims
Boehringer IngelheimJardiance$219$24,49720 claims
Novo NordiskOzempic$231$18,29714 claims
GSKTrelegy Ellipta$163$16,35519 claims
Lilly USA, LLCMounjaro$292$14,84414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Bandera

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →